公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
2019 | First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma | Kim R.D.; Sarker D.; Meyer T.; Yau T.; Macarulla T.; Park J.-W.; Choo S.P.; Hollebecque A.; Sung M.W.; Lim H.-Y.; Mazzaferro V.; Trojan J.; Zhu A.X.; Yoon J.-H.; Sharma S.; ZHONG-ZHE LIN ; Chan S.L.; Faivre S.; Feun L.G.; Yen C.-J.; Dufour J.-F.; Palmer D.H.; Llovet J.M.; Manoogian M.; Tugnait M.; Stransky N.; Hagel M.; Kohl N.E.; Lengauer C.; Sherwin C.A.; Schmidt-Kittler O.; Hoeflich K.P.; Shi H.; Wolf B.B.; Kang Y.-K. | Cancer Discovery | 154 | 136 | |
2009 | Gastric perforation presenting as empyema in a patient with pancreatic cancer on bevacizumab treatment | YU-YUN SHAO ; ZHONG-ZHE LIN ; PO-CHIN LIANG ; YU-WEN TIEN ; ANN-LII CHENG | Anticancer Research | 1 | 1 | |
2009 | Gemcitabine-based combination chemotherapy as salvage treatment for refractory or relapsing aggressive non-Hodgkin's lymphoma | SHIH-HUNG YANG ; ZHONG-ZHE LIN ; SUNG-HSIN KUO ; ANN-LII CHENG | American Journal of Hematology | 1 | 1 | |
2010 | Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; Huang C.; PO-CHIN LIANG ; ZHONG-ZHE LIN | Asia-Pacific Journal of Clinical Oncology | 29 | 29 | |
2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
2008 | High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy | Perng R.-P.; CHIH-HSIN YANG ; Chen Y.-M.; Chang G.-C.; Lin M.-C.; Hsieh R.-K.; Chu N.-M.; Lai R.-S.; Su W.-C.; Tsao C.-J.; Hsia T.-C.; Chen H.-C.; Chen C.-H.; Huang M.-S.; Wang J.-L.; Ho M.-L.; Chung C.-Y.; CHONG-JEN YU ; Chang W.-C.; Kuo H.-P.; Yu C.-T.; ZHONG-ZHE LIN ; Kao W.-Y. | Lung Cancer | 28 | 26 | |
2013 | Hospital volume of percutaneous radiofrequency ablation is closely associated with treatment outcomes for patients with hepatocellular carcinoma | LI-CHUN LU ; YU-YUN SHAO ; Kuo R.N.C.; ZHONG-ZHE LIN ; Yeh Y.-C.; Shau W.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG ; Lai M.-S. | Cancer | 11 | 11 | |
2011 | Impact of baseline hepatitis B viral DNA levels on survival of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; PEI-JER CHEN ; ZHONG-ZHE LIN ; Huang C.-C.; Ding Y.-H.; Lee Y.-H.; CHIH-HUNG HSU ; ANN-LII CHENG | Anticancer Research | 12 | ||
2012 | The impact of diabetes mellitus on prognosis of early breast cancer in Asia | WEI-WU CHEN ; YU-YUN SHAO ; Shau W.-Y.; ZHONG-ZHE LIN ; YEN-SHEN LU ; Chen H.-M.; Kuo R.N.C.; ANN-LII CHENG ; Lai M.-S. | Oncologist | 36 | 34 | |
2019 | Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non–small-cell lung cancer patients | ZONG-HAN YAO ; WEI-YU LIAO ; CHAO-CHI HO ; KUAN-YU CHEN ; JIN-YUAN SHIH ; JIN-SHING CHEN ; ZHONG-ZHE LIN ; CHIA-CHI LIN ; CHIH-HSIN YANG ; CHONG-JEN YU | European Journal of Cancer | 27 | 24 | |
2019 | Klotho-beta and fibroblast growth factor 19 expression correlates with early recurrence of resectable hepatocellular carcinoma | ZHONG-ZHE LIN ; CHIUN HSU ; YUNG-MING JENG ; Hu F.-C.; Pan H.-W.; YAO-MING WU ; Hsu H.-C.; ANN-LII CHENG | Liver International | 18 | 18 | |
2017 | Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy | YU-YUN SHAO ; BANG-BIN CHEN ; DA-LIANG OU ; ZHONG-ZHE LIN ; CHIH-HUNG HSU ; Wang, M. J.; ANN-LII CHENG ; CHIUN HSU | Alimentary Pharmacology and Therapeutics | 10 | 8 | |
2021 | Limited predictive or prognostic role of tumor-infiltrating tissue-resident memory cd8 t cells in patients with hepatocellular carcinoma receiving immunotherapy | YING-CHUN SHEN ; Yeh C.-P.; YUNG-MING JENG ; CHIUN HSU ; CHIH-HUNG HSU ; ZHONG-ZHE LIN ; YU-YUN SHAO ; LI-CHUN LU ; TSUNG-HAO LIU ; CHIEN-HUNG CHEN ; ANN-LII CHENG | Cancers | 2 | 2 | |
2022 | The Long-Term and Mediating Effects of Mindfulness Integrated with Body-Mind-Spirit Group Therapy on Depressive Symptoms and Quality of Life Among Non-small Cell Lung Cancer Patients | FEI-HSIU HSIAO ; ZHONG-ZHE LIN ; Huang F.-Y.; Lai Y.-M.; Chen Y.-T.; JIN-YUAN SHIH ; CHAO-CHI HO ; CHONG-JEN YU ; Hsieh C.-C. | Mindfulness | 1 | 1 | |
2020 | A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy | ZHONG-ZHE LIN ; BANG-BIN CHEN ; Hung, Yi-Ping; HUANG, PO-HSIANG ; Ying-Chun Shen ; YU-YUN SHAO ; CHIH-HUNG HSU ; ANN-LII CHENG ; Lee, Rheun-Chuan; Chao, Yee; CHIUN HSU | Oncologist | 12 | 10 | |
2009 | Nuclear overexpression of mitotic regulatory proteins in biliary tract cancer: Correlation with clinicopathologic features and patient survival | Ying-Chun Shen ; Hu F.-C.; YUNG-MING JENG ; YU-TING CHANG ; ZHONG-ZHE LIN ; MING-CHU CHANG ; CHIUN HSU ; ANN-LII CHENG | Cancer Epidemiology Biomarkers and Prevention | 21 | 20 | |
2008 | Outcome of advanced nonsmall cell lung cancer patients receiving gemcitabine and weekly paclitaxel as first-line treatment | ZHONG-ZHE LIN ; CHIUN HSU ; YEUN-CHUNG CHANG ; CHONG-JEN YU ; CHIH-HUNG HSU ; CHIA-CHI LIN ; ANN-LII CHENG ; PAN-CHYR YANG ; CHIH-HSIN YANG | Lung Cancer | 5 | 1 | |
2012 | A phase I and pharmacokinetic study of liposomal vinorelbine in patients with advanced solid tumor | SHIH-HUNG YANG ; CHIA-CHI LIN ; ZHONG-ZHE LIN ; Tseng Y.-L.; RUEY-LONG HONG | Investigational New Drugs | 34 | 28 | |
2017 | Phase Ib study of codrituzumab in combination with sorafenib in patients with non-curable advanced hepatocellular carcinoma (HCC) | Abou-Alfa G.K.; Yen C.-J.; CHIH-HUNG HSU ; O��Donoghue J.; Beylergil V.; Ruan S.; Pandit-Taskar N.; Gansukh B.; Lyashchenko S.K.; Ma J.; Wan P.; YU-YUN SHAO ; ZHONG-ZHE LIN ; Frenette C.; O��Neil B.; Schwartz L.; Smith-Jones P.M.; Ohtomo T.; Tanaka T.; Morikawa H.; Maki Y.; Ohishi N.; Chen Y.-C.; Agajanov T.; Boisserie F.; Di Laurenzio L.; Lee R.; Larson S.M.; ANN-LII CHENG ; Carrasquilo J.A. | Cancer Chemotherapy and Pharmacology | 20 | 19 |